Thirty specimens of human endometrial carcinoma (n = 23) and cervical adenocarcinoma (n = 1) have been analyzed for c-myc, epidermal growth factor receptor (EGFR) and c-erbB-2 by immunohistochemistry. In endometrial carcinomas, expression of c-myc was observed in all cases, EGFR in 21 of 23 cases (91.3%) and c-erbB-2 in 7 of 23 cases (30.4%). In cervical adenocarcinomas, expression of c-myc was seen in 5 of 7 cases (71.6%), EGFR in all cases and c-erbB-2 in 2 of 7 cases (28.6%). c-myc immunoactivity was observed as nuclear or cytoplasmic stain or both, EGFR as membrane and cytoplasmic stain, c-erbB-2 as menbrane stain. There was no relationship between expression of these three oncogenes and clinical prognostic factors in the present study. © 1991, Tohoku University Medical Press. All rights reserved.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Sato, S., Ito, K., Ozawa, N., Yajima, A., & Sasano, H. (1991). Expression of c-myc, Epidermal Growth Factor Receptor and c-erbB-2 in Human Endometrial Carcinoma and Cervical Adenocarcinoma. Tohoku Journal of Experimental Medicine, 165(2), 137–145. https://doi.org/10.1620/tjem.165.137